Shanghai Medicilon, Inc. is a leading pharmaceutical company based in China. With an ESG score of 19.5, the company has been assessed as low risk. Specializing in biomedical research and development, Shanghai Medicilon offers a wide range of new drug development services to pharmaceutical companies and research institutions globally. They adhere to both domestic and international reporting standards, making them a trusted partner in the industry.